Aligos Therapeutics Q4 Revenue $169K, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ALGS?
Reports Q4 revenue $169k, consensus $266.67k. "Our team has made tremendous progress recently in the global Phase 2 B-SUPREME study of pevifoscorvir sodium," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "With the completion of the planned enrollment in the HBeAg- cohort, we are continuing to enroll participants in the HBeAg+ cohort and look forward to the interim analyses in the first and second half of 2026. Additionally, the Phase 2 B-SUPREME study may demonstrate that pevifoscorvir sodium affects the three pillars of HBV disease pathogenesis: replication, integration, and maintenance of the viral reservoir. We are also excited to announce the advancement, in partnership with Xiamen Amoytop Biotech Co., of ALG-170675, a dual mechanism antisense oligonucleotide into IND-enabling studies. Lastly, adding James Hassard as Executive Vice President, Chief Commercial Officer has allowed us to begin laying the groundwork for the future of our best-in-class programs."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGS
Wall Street analysts forecast ALGS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.025
Low
20.00
Averages
81.67
High
175.00
Current: 7.025
Low
20.00
Averages
81.67
High
175.00
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements
- Reduced Financial Losses: Aligos Therapeutics reported a net loss of $19.9 million for Q4 2025, translating to a basic and diluted net loss per share of $(1.91), a significant improvement from the $82.2 million loss and $(13.08) per share in Q4 2024, indicating progress in cost management and operational efficiency.
- Pipeline Advancements: The company’s drug pipeline includes Pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675, all advancing through clinical and preclinical stages, particularly with Pevifoscorvir sodium in the B-SUPREME study expected to yield key data in 2027, potentially offering new hope for chronic hepatitis B treatment.
- Promising Drug Research: ALG-055009 demonstrated up to 39-40% weight loss in animal studies when combined with weight loss drugs, suggesting it could enhance existing treatment effects, and the company is exploring partnership opportunities for further development, indicating potential market value.
- Strong Financial Position: As of December 31, 2025, Aligos had $77.8 million in cash and equivalents, expected to fund operations into Q3 2026, reflecting financial stability for ongoing R&D and market expansion efforts.
See More
Aligos Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Aligos Therapeutics reported a Q4 GAAP EPS of -$1.91, beating market expectations by $0.12, indicating improvements in cost control and operational efficiency despite still being in a loss position.
- Market Reaction: Following the earnings release, Aligos's stock price may experience a positive impact, as investor confidence in the company's future profitability and financial health is likely to strengthen, reflecting market expectations for a potential recovery.
- Historical Data Comparison: Compared to historical earnings data, the improvement in EPS, although still negative, suggests that the company's efforts in R&D and operations are gradually yielding results, potentially laying the groundwork for future growth.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, Aligos Therapeutics's stock performance is under scrutiny, and analysts may reassess its investment value, further influencing market perceptions of the company.
See More
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
- Leadership Change: Onco3R Therapeutics announced the appointment of Dr. Lawrence M. Blatt as Chair of the Board, bringing extensive drug development and strategic leadership experience to guide the company's next growth phase.
- Industry Expertise: Blatt has served as CEO of Aligos Therapeutics since 2018 and previously led global infectious diseases and vaccines at Janssen Pharmaceuticals, providing a strong industry background.
- Product Development Potential: Onco3R's O3R-5671, designed for autoimmune diseases based on over 12 years of preclinical and clinical data, shows promising safety and efficacy, with potential applications in various autoimmune conditions.
- Clinical Trial Plans: The Phase 1 trial for O3R-5671 is set to commence in 2026, assessing safety and pharmacokinetics while utilizing biomarker tests to gain insights into its immune modulation mechanisms.
See More
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
- Stock Option Grant: Aligos Therapeutics granted a total of 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting top talent and enhancing employee loyalty, in compliance with Nasdaq listing rules.
- Incentive Plan Implementation: The stock options were granted under Aligos' 2024 Inducement Plan, ensuring that new hires benefit from equity incentives during their tenure, thereby improving overall team stability and execution.
- Exercise Price Setting: The exercise price of the stock options is set at the closing price on the grant date, ensuring that new employees can share in the value growth of the company, further motivating them to contribute to its development.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only helps retain talent but also aligns employee goals with the company's objectives.
See More
Aligos Grants 14,100 Stock Options to New Employees as Inducement
- Incentive Program Launch: Aligos Therapeutics granted 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting high-quality talent and strengthening the team to drive the company's R&D progress in liver and viral diseases.
- Equity Incentive Structure: The stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring long-term employee retention and enhancing company stability.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company adheres to relevant regulations while attracting new employees, thereby reducing compliance risks and enhancing corporate image.
- Strategic Talent Acquisition: By implementing this incentive measure, Aligos not only attracts new talent but also accelerates its innovation process in liver and viral disease treatments through enhanced team expertise, further improving its market competitiveness.
See More
Aligos Therapeutics Presents Positive HBV and Weight Loss Data at HEP-DART 2025
- HBV Treatment Potential: Aligos showcased positive data from a 96-week study of 300mg pevifoscorvir sodium monotherapy at HEP-DART 2025, indicating its potential as a first-line therapy for chronic hepatitis B, thereby reinforcing the company's leadership in the liver disease sector.
- Significant Weight Loss Effects: New data reveals that the combination of ALG-055009 with semaglutide can achieve up to 40% weight loss, significantly enhancing efficacy compared to monotherapy, highlighting its potential value in treating obesity and metabolic diseases.
- Clinical Research Advancements: In diet-induced obese mice, the combination of ALG-055009 with incretin receptor agonists demonstrated synergistic effects, further validating its importance in future combination therapies and potentially increasing the company's market share in the cardiometabolic space.
- Commitment to Continuous Innovation: Aligos has made promising advancements in early-stage HBV and HDV research, showcasing its ongoing commitment to developing next-generation therapies in liver and viral diseases, which enhances investor confidence in its future growth potential.
See More
Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements
- Reduced Financial Losses: Aligos Therapeutics reported a net loss of $19.9 million for Q4 2025, translating to a basic and diluted net loss per share of $(1.91), a significant improvement from the $82.2 million loss and $(13.08) per share in Q4 2024, indicating progress in cost management and operational efficiency.
- Pipeline Advancements: The company’s drug pipeline includes Pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675, all advancing through clinical and preclinical stages, particularly with Pevifoscorvir sodium in the B-SUPREME study expected to yield key data in 2027, potentially offering new hope for chronic hepatitis B treatment.
- Promising Drug Research: ALG-055009 demonstrated up to 39-40% weight loss in animal studies when combined with weight loss drugs, suggesting it could enhance existing treatment effects, and the company is exploring partnership opportunities for further development, indicating potential market value.
- Strong Financial Position: As of December 31, 2025, Aligos had $77.8 million in cash and equivalents, expected to fund operations into Q3 2026, reflecting financial stability for ongoing R&D and market expansion efforts.
See More
Aligos Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Aligos Therapeutics reported a Q4 GAAP EPS of -$1.91, beating market expectations by $0.12, indicating improvements in cost control and operational efficiency despite still being in a loss position.
- Market Reaction: Following the earnings release, Aligos's stock price may experience a positive impact, as investor confidence in the company's future profitability and financial health is likely to strengthen, reflecting market expectations for a potential recovery.
- Historical Data Comparison: Compared to historical earnings data, the improvement in EPS, although still negative, suggests that the company's efforts in R&D and operations are gradually yielding results, potentially laying the groundwork for future growth.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, Aligos Therapeutics's stock performance is under scrutiny, and analysts may reassess its investment value, further influencing market perceptions of the company.
See More
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
- Leadership Change: Onco3R Therapeutics announced the appointment of Dr. Lawrence M. Blatt as Chair of the Board, bringing extensive drug development and strategic leadership experience to guide the company's next growth phase.
- Industry Expertise: Blatt has served as CEO of Aligos Therapeutics since 2018 and previously led global infectious diseases and vaccines at Janssen Pharmaceuticals, providing a strong industry background.
- Product Development Potential: Onco3R's O3R-5671, designed for autoimmune diseases based on over 12 years of preclinical and clinical data, shows promising safety and efficacy, with potential applications in various autoimmune conditions.
- Clinical Trial Plans: The Phase 1 trial for O3R-5671 is set to commence in 2026, assessing safety and pharmacokinetics while utilizing biomarker tests to gain insights into its immune modulation mechanisms.
See More
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
- Stock Option Grant: Aligos Therapeutics granted a total of 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting top talent and enhancing employee loyalty, in compliance with Nasdaq listing rules.
- Incentive Plan Implementation: The stock options were granted under Aligos' 2024 Inducement Plan, ensuring that new hires benefit from equity incentives during their tenure, thereby improving overall team stability and execution.
- Exercise Price Setting: The exercise price of the stock options is set at the closing price on the grant date, ensuring that new employees can share in the value growth of the company, further motivating them to contribute to its development.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only helps retain talent but also aligns employee goals with the company's objectives.
See More
Aligos Grants 14,100 Stock Options to New Employees as Inducement
- Incentive Program Launch: Aligos Therapeutics granted 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting high-quality talent and strengthening the team to drive the company's R&D progress in liver and viral diseases.
- Equity Incentive Structure: The stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring long-term employee retention and enhancing company stability.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company adheres to relevant regulations while attracting new employees, thereby reducing compliance risks and enhancing corporate image.
- Strategic Talent Acquisition: By implementing this incentive measure, Aligos not only attracts new talent but also accelerates its innovation process in liver and viral disease treatments through enhanced team expertise, further improving its market competitiveness.
See More
Aligos Therapeutics Presents Positive HBV and Weight Loss Data at HEP-DART 2025
- HBV Treatment Potential: Aligos showcased positive data from a 96-week study of 300mg pevifoscorvir sodium monotherapy at HEP-DART 2025, indicating its potential as a first-line therapy for chronic hepatitis B, thereby reinforcing the company's leadership in the liver disease sector.
- Significant Weight Loss Effects: New data reveals that the combination of ALG-055009 with semaglutide can achieve up to 40% weight loss, significantly enhancing efficacy compared to monotherapy, highlighting its potential value in treating obesity and metabolic diseases.
- Clinical Research Advancements: In diet-induced obese mice, the combination of ALG-055009 with incretin receptor agonists demonstrated synergistic effects, further validating its importance in future combination therapies and potentially increasing the company's market share in the cardiometabolic space.
- Commitment to Continuous Innovation: Aligos has made promising advancements in early-stage HBV and HDV research, showcasing its ongoing commitment to developing next-generation therapies in liver and viral diseases, which enhances investor confidence in its future growth potential.
See More
